ATNM – actinium pharmaceuticals, inc. (delaware) (US:NASDAQ)
Stock Stats
News
11/19
01:22 pm
atnm
Low
Actinium Pharmaceuticals, Inc. (NYSE: ATNM) had its "overweight" rating re-affirmed by analysts at Stephens. They now have a $5.00 price target on the stock.
11/18
08:12 am
atnm
Medium
Actinium Pharmaceuticals Highlights Antibody Radiation Conjugate Program Developments and Reports Financial Results for the Third Quarter 2024 [Yahoo! Finance]
11/18
08:00 am
atnm
Medium
Actinium Pharmaceuticals Highlights Antibody Radiation Conjugate Program Developments and Reports Financial Results for the Third Quarter 2024
11/15
03:26 pm
atnm
Low
Actinium Pharmaceuticals, Inc. (NYSE: ATNM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
11/11
11:10 pm
atnm
Medium
Actinium Pharmaceuticals, Inc. (NYSE: ATNM) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
11/14/2024
04:57 pm
ATNM
-8.5%
MISS
11/19
01:22 pm
Reiterates
Overweight
Overweight
Stephens
Low
-1.4%
11/19
01:22 pm
Reiterates
Overweight
Overweight
Stephens
Low
-1.4%
11/19
12:52 pm
Reiterates
Overweight
Overweight
Stephens & Co.
Low
-0.7%
11/15
03:26 pm
Reiterates
Buy
Buy
HC Wainwright
Low
2.4%
11/27
04:30 pm
atnm
Neutral
Form 8-K Actinium Pharmaceuticals For: Nov 27
11/14
04:58 pm
atnm
High
Form 10-Q Actinium Pharmaceuticals For: Sep 30
11/12
01:33 pm
atnm
Medium
Form SC 13G/A Actinium Pharmaceuticals Filed by: VANGUARD GROUP INC
11/8
06:51 pm
atnm
Low
Form SC 13G/A Actinium Pharmaceuticals Filed by: Bigger Capital, LLC
11/6
07:31 am
atnm
Medium
Form ARS Actinium Pharmaceuticals For: Dec 31
Show more
Top News Gainers
10/24 Actinium to Announce Interim Results from Pivotal Phase 3 SIERRA Trial on Conference Call Scheduled for Monday, October 28th 37.9%
3/5 Actinium Pharmaceuticals Announces First Patient Treated in Third and Final Dose Cohort of Actimab-A CLAG-M Combination Phase 1 Trial in Acute Myeloid Leukemia 20.8%
7/23 Actinium Achieves Fifty Percent Enrollment in the Pivotal Phase 3 SIERRA Trial for Iomab-B 14.3%
1/13 Actinium Pharmaceuticals Announces Iomab-ACT Program Gene Therapy Collaboration with UC Davis in Ongoing Clinical Trial for Patients with HIV-Related Lymphoma 14.2%
9/23 Actinium Announces Iomab-B Poster Selected for Honorable Distinction Award at the 2019 Society of Hematologic Oncology Annual Meeting from Nearly Four Hundred Abstracts 8.1%
4/22 Form 424B5 Actinium Pharmaceuticals 3.9%
5/16 Abstract Highlighting New Data from the Iomab-B Pivotal Phase 3 SIERRA Trial to be Presented at 2019 ASCO Annual Meeting 3.8%
8/9 Q2/2019 6/30/2019 EPS -0.030 ZacksConsensus N/A ActVsEst N/A - N/A 3.2%
2/13 Actinium to Highlight Targeted Conditioning Portfolio at 2020 Transplantation & Cellular Therapy Annual Meeting; Phase 3 SIERRA Trial Preliminary Results Selected for Oral Presentation 2.5%
1/7 Actinium Pharmaceuticals, Inc. to Present at 2020 Biotech Showcase™ 2.3%
Top News Decliners
10/28 Actinium Announces Positive Interim Results from Iomab-B Pivotal Phase 3 SIERRA Trial at 50% of Total Patient Enrollment -28.9%
4/21 Actinium Pharmaceuticals, Inc. Announces Proposed Public Offering -25.8%
11/15 Form PRE 14A Actinium Pharmaceuticals For: Nov 15 -15.0%
6/25 Actinium Presents New Data Demonstrating Effective Lymphodepletion with Lutetium-177 for CAR-T at the 2019 Society of Nuclear Medicine and Molecular Imaging Annual Meeting -14.0%
12/9 Actinium Pharmaceuticals Highlights 86% Response Rate and 71% MRD Negative Rate in Actimab-A CLAG-M Combination Trial in Patients with Relapsed or Refractory AML at ASH 2019 Annual Meeting -13.1%
3/5 Actinium Pharma up 24% on advancement of Actimab-A in AML [Seeking Alpha] -11.8%
2/21 Actinium Pharma up 17% premarket on encouraging Iomab-B data [Seeking Alpha] -11.0%
12/3 Form 8-K Actinium Pharmaceuticals For: Dec 02 -7.0%
6/4 Actinium Presents New Pivotal Phase 3 SIERRA Trial Data Showing Rapid Peripheral Blast Reduction and Anti-Leukemic Effect with Single Agent Iomab-B in Older Patients with Active, Relapsed or Refractory Acute Myeloid Leukemia at 2019 ASCO Annual Meeting -4.5%
11/12 Q3/2019 9/30/2019 EPS -0.040 ZacksConsensus -0.040 ActVsEst 0.000 - In-Line -4.5%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.
Click Here To Register For The Live Online Workshop
In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

20715 N Pima Rd #F108
Scottsdale, AZ 85255
Email: info@newsquantified.com
Copyright Ⓒ News Quanitifed LLC. 1.1.3